Nilotinib + Radiation for Chordoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding nilotinib, a medication believed to slow tumor growth, can enhance the effects of radiation therapy for chordoma, a rare cancer. The main goal is to determine the safest dose of nilotinib to use with radiation without causing serious side effects. Suitable participants have a confirmed chordoma diagnosis, consider their disease high-risk, and can swallow pills. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this potentially groundbreaking therapy.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you must stop taking your current medications, but you cannot participate if you are currently receiving treatment with strong CYP3A4 inhibitors or require anticoagulation with coumadin.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that using nilotinib with radiation therapy is safe for patients with high-risk chordoma. Studies found that a 200 mg daily dose of nilotinib with radiation was generally well-tolerated. Although the long-term effects are still under investigation, serious heart-related side effects, such as changes in heart function, are rare. While this trial is in an early stage, past use of nilotinib suggests it can be safely combined with radiation without adding significant risk.12345
Why do researchers think this study treatment might be promising?
Nilotinib offers a promising new approach for treating chordoma because it targets specific pathways involved in cancer cell growth that are not addressed by current treatments. Most standard therapies for chordoma rely primarily on surgery and radiation, but nilotinib is a tyrosine kinase inhibitor that works by blocking signals that promote tumor growth. Researchers are excited about its potential to enhance the effects of radiation therapy, potentially improving outcomes for patients who have limited options beyond traditional methods.
What evidence suggests that nilotinib combined with radiation therapy could be effective for chordoma?
Research has shown that using nilotinib with radiation therapy, the treatment combination under study in this trial, may help slow the growth of chordoma tumors. Specifically, patients who received this combination in studies had a median progression-free survival of about 58 months, meaning many experienced a delay in tumor growth for nearly five years. Additionally, the two-year overall survival rate was 95%, indicating a strong potential for extending life with this treatment. Nilotinib targets a specific gene that controls cell growth in chordoma tumors.13567
Who Is on the Research Team?
Edwin Choy, MD
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for individuals with high-risk chordoma, a type of bone cancer. Participants must have a life expectancy over 3 months, be able to swallow capsules, and have measurable disease with proper organ function. It's not open to those who've had certain heart issues, are on strong CYP3A4 inhibitors or anticoagulants like coumadin, have gastrointestinal problems affecting drug absorption, acute pancreatitis, CNS infiltration by cancer cells, another primary cancer needing treatment, recent major surgery without recovery or investigational agent use within the last month.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Nilotinib Treatment
Participants receive nilotinib orally daily for 2 weeks before starting radiation therapy
Radiation Therapy
Participants receive daily radiation therapy concurrently with nilotinib until Day 56
Extended Radiation Therapy
If surgery is not possible, an additional 3 weeks of radiation therapy is applied
Follow-up
Participants are monitored for safety and effectiveness after treatment with tumor assessments every 6 months for one year, then annually
What Are the Treatments Tested in This Trial?
Interventions
- Nilotinib
- Radiation therapy
Trial Overview
The study tests Nilotinib combined with radiation therapy in treating advanced chordomas. Nilotinib is believed to slow tumor growth by targeting specific genes in the tumor cells. The goal is to find out how safe this combination is and the highest dose of Nilotinib that can be given safely alongside standard radiation treatments.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
Nilotinib is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
- Chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib
- Chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adult patients resistant to or intolerant to prior therapy that included imatinib
- Chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib
- Chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib
- Chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Citations
A Phase 1 Study of Nilotinib Plus Radiation in High-Risk ...
The objective best response rate was 6% (1 of 18 patients, 95% confidence interval [CI], 0.1%-27%). The median progression-free survival was ...
A Phase 1 Study of Nilotinib Plus Radiation in High-Risk ...
In this phase 1 clinical trial, patients with high-risk chordoma were treated with a combination of nilotinib plus radiation with or without surgical resection.
Updated 5-year local control (LC), metastasis-free survival ...
The 4 and 5-year OS rates were 70.2% (95% CI 44.4-95.9) and 54.6% (95% CI 20.5-88.6). Conclusions: In updated data from a cohort of high-risk ...
4.
researchgate.net
researchgate.net/publication/326810063_A_Phase_1_Study_of_Nilotinib_Plus_Radiation_in_High-Risk_ChordomaA Phase 1 Study of Nilotinib Plus Radiation in High-Risk ...
The results of their study showed that the median PFS was 58.15 months, with a 2-year overall survival rate was 95% (24) .
Nilotinib + Radiation for Chordoma · Info for Participants
The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells.
Nilotinib With Radiation for High Risk Chordoma | ...
The purpose of this research study is to determine the safety of nilotinib when used in combination with radiation therapy, and the highest dose of ...
Clinical cardiac safety profile of nilotinib - PMC
QT prolongation, changes in left ventricular ejection fraction, and clinical cardiac adverse events were uncommon in patients treated with nilotinib.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.